Live Evaluations

The Role of JAK Inhibitors in the Management of Pediatric Patients with Atopic Dermatitis: PEDS23 Seminar-in-Depth


CME Seminar in Depth - May 6, 2023 2:35 PM EST

 The Role of JAK Inhibitors in the Management of Pediatric Patients with Atopic Dermatitis

This activity is supported by an educational grant from Incyte. 

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Review the multiple inflammatory pathways in AD

  • Recall key data on the use of JAK inhibitors to manage AD in pediatric patients

  • Discuss strategies to improve the standard of care in pediatric AD with advanced therapies

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers


In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


The leading platform for dermatology professionals to elevate patient care.

Contact Us


Subscribe now

Enter your email to get the latest updates.

© 2023 dermsquared | All Rights Reserved